229 related articles for article (PubMed ID: 34521466)
1. Effect of Lycium barbarum polysaccharide supplementation in non-alcoholic fatty liver disease patients: study protocol for a randomized controlled trial.
Gao LL; Li YX; Ma JM; Guo YQ; Li L; Gao QH; Fan YN; Zhang MW; Tao XJ; Yu JQ; Yang JJ
Trials; 2021 Aug; 22(1):566. PubMed ID: 34521466
[TBL] [Abstract][Full Text] [Related]
2. Lycium barbarum polysaccharide combined with aerobic exercise ameliorated nonalcoholic fatty liver disease through restoring gut microbiota, intestinal barrier and inhibiting hepatic inflammation.
Gao LL; Ma JM; Fan YN; Zhang YN; Ge R; Tao XJ; Zhang MW; Gao QH; Yang JJ
Int J Biol Macromol; 2021 Jul; 183():1379-1392. PubMed ID: 33992651
[TBL] [Abstract][Full Text] [Related]
3. A homogeneous polysaccharide from Lycium barbarum: Structural characterizations, anti-obesity effects and impacts on gut microbiota.
Yang Y; Chang Y; Wu Y; Liu H; Liu Q; Kang Z; Wu M; Yin H; Duan J
Int J Biol Macromol; 2021 Jul; 183():2074-2087. PubMed ID: 34097961
[TBL] [Abstract][Full Text] [Related]
4. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol.
Lambert JE; Parnell JA; Eksteen B; Raman M; Bomhof MR; Rioux KP; Madsen KL; Reimer RA
BMC Gastroenterol; 2015 Dec; 15():169. PubMed ID: 26635079
[TBL] [Abstract][Full Text] [Related]
5.
Cui F; Shi CL; Zhou XJ; Wen W; Gao XP; Wang LY; He B; Yin M; Zhao JQ
J Med Food; 2020 Jul; 23(7):699-710. PubMed ID: 32392444
[TBL] [Abstract][Full Text] [Related]
6. Dietary supplementation with Lycium barbarum polysaccharides conducive to maintaining the health of Luciobarbus capito via the enhancement of enzyme activities and the modulation of gut microbiota.
Sun Y; Meng X; Hu X; Liu R; Zhao Z; Wang S; Zhang R; Guo K; Luo L
Int J Biol Macromol; 2023 Mar; 232():123500. PubMed ID: 36736520
[TBL] [Abstract][Full Text] [Related]
7. Effect of Daesiho-tang on obesity with non-alcoholic fatty liver disease: a study protocol for a randomised, double-blind, placebo-controlled pilot trial.
Han K; Kwon O; Park HJ; Jung SY; Yang C; Son CG
Trials; 2020 Jan; 21(1):128. PubMed ID: 32005283
[TBL] [Abstract][Full Text] [Related]
8. Prebiotic, immuno-stimulating and gut microbiota-modulating effects of Lycium barbarum polysaccharide.
Zhu W; Zhou S; Liu J; McLean RJC; Chu W
Biomed Pharmacother; 2020 Jan; 121():109591. PubMed ID: 31733576
[TBL] [Abstract][Full Text] [Related]
9.
Xia H; Zhou B; Sui J; Ma W; Wang S; Yang L; Sun G
Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231391
[TBL] [Abstract][Full Text] [Related]
10. Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial.
Naeini F; Namkhah Z; Tutunchi H; Rezayat SM; Mansouri S; Jazayeri-Tehrani SA; Yaseri M; Hosseinzadeh-Attar MJ
Trials; 2021 Nov; 22(1):801. PubMed ID: 34774104
[TBL] [Abstract][Full Text] [Related]
11. Traditional Chinese medicine Lingguizhugan decoction treating non-alcoholic fatty liver disease with spleen-yang deficiency pattern: Study protocol for a multicenter randomized controlled trial.
Xu J; Wang R; You S; Zhang L; Zheng P; Ji G; Liu B
Trials; 2020 Jun; 21(1):512. PubMed ID: 32522273
[TBL] [Abstract][Full Text] [Related]
12. Lycium barbarum polysaccharide mitigated methamphetamine addiction and altered methamphetamine-induced gut microbiota dysbiosis.
Zhuang J; Chen Q; Xu L; Qiao D; Chen X
Electrophoresis; 2024 May; 45(9-10):958-969. PubMed ID: 38528319
[TBL] [Abstract][Full Text] [Related]
13. Supplementation of
Li DD; Ma JM; Li MJ; Gao LL; Fan YN; Zhang YN; Tao XJ; Yang JJ
Nutrients; 2022 Aug; 14(15):. PubMed ID: 35956423
[TBL] [Abstract][Full Text] [Related]
14. Effect of a prebiotic supplement on knee joint function, gut microbiota, and inflammation in adults with co-morbid obesity and knee osteoarthritis: study protocol for a randomized controlled trial.
Fortuna R; Hart DA; Sharkey KA; Schachar RA; Johnston K; Reimer RA
Trials; 2021 Apr; 22(1):255. PubMed ID: 33827639
[TBL] [Abstract][Full Text] [Related]
15. Lycium barbarum polysaccharide attenuates myocardial injury in high-fat diet-fed mice through manipulating the gut microbiome and fecal metabolome.
Zhang Z; Liu H; Yu B; Tao H; Li J; Wu Z; Liu G; Yuan C; Guo L; Cui B
Food Res Int; 2020 Dec; 138(Pt B):109778. PubMed ID: 33288164
[TBL] [Abstract][Full Text] [Related]
16. Effects of vitamin D supplementation on liver fibrogenic factors in non-alcoholic fatty liver patients with steatohepatitis: study protocol for a randomized clinical trial.
Ebrahimpour-Koujan S; Sohrabpour AA; Foroughi F; Alvandi E; Esmaillzadeh A
Trials; 2019 Mar; 20(1):153. PubMed ID: 30832722
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of silymarin in patients with non-alcoholic fatty liver disease - the Siliver trial: a study protocol for a randomized controlled clinical trial.
de Avelar CR; Nunes BVC; da Silva Sassaki B; Dos Santos Vasconcelos M; de Oliveira LPM; Lyra AC; Bueno AA; de Jesus RP
Trials; 2023 Mar; 24(1):177. PubMed ID: 36899430
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design.
Kessoku T; Imajo K; Kobayashi T; Honda Y; Kato T; Ogawa Y; Tomeno W; Kato S; Higurashi T; Yoneda M; Kirikoshi H; Kubota K; Taguri M; Yamanaka T; Usuda H; Wada K; Saito S; Nakajima A
Contemp Clin Trials; 2018 Jun; 69():40-47. PubMed ID: 29627620
[TBL] [Abstract][Full Text] [Related]
19. Serum metabolomics combined with 16S rRNA sequencing to reveal the effects of Lycium barbarum polysaccharide on host metabolism and gut microbiota.
Liang J; Li X; Lei W; Tan P; Han M; Li H; Yue T; Wang Z; Gao Z
Food Res Int; 2023 Mar; 165():112563. PubMed ID: 36869545
[TBL] [Abstract][Full Text] [Related]
20. Effect of aerobic exercise and low carbohydrate diet on pre-diabetic non-alcoholic fatty liver disease in postmenopausal women and middle aged men--the role of gut microbiota composition: study protocol for the AELC randomized controlled trial.
Liu WY; Lu DJ; Du XM; Sun JQ; Ge J; Wang RW; Wang R; Zou J; Xu C; Ren J; Wen XF; Liu Y; Cheng SM; Tan X; Pekkala S; Munukka E; Wiklund P; Chen YQ; Gu Q; Xia ZC; Liu JJ; Liu WB; Chen XB; Zhang YM; Li R; Borra RJ; Yao JX; Chen PJ; Cheng S
BMC Public Health; 2014 Jan; 14():48. PubMed ID: 24438438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
